Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Yin Z. et al, (2023), Cell Rep, 42
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH. et al, (2023), J Infect
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Dijokaite-Guraliuc A. et al, (2023), Cell reports, 42
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Moore SC. et al, (2023), Med (N Y)
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies.
Davies AJ. et al, (2023), Neurology(R) neuroimmunology & neuroinflammation, 10
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.
Huo J. et al, (2022), Cell reports
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever.
Shu B. et al, (2022), Nature communications, 13
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.
Huo J. et al, (2022), Cell discovery, 8
Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom
Vihta1 KD. et al, (2022), Clinical Infectious Diseases
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), The Lancet. Respiratory medicine
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu X. et al, (2022), The Journal of infection, 84, 795 - 813
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18
Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework
Chenthamarakshan V. et al, (2022)
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
McNaughton AL. et al, (2022), JCI insight
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon A. et al, (2022)